About MARAbio

MARAbio utilizes a maternal blood test to detect the presence of specific autoantibodies associated with Maternal Autoantibody Related Autism (MARA), achieving over 90% predictive accuracy for severe autism in children before clinical symptoms appear. This early detection enables healthcare providers to implement tailored interventions, improving outcomes for affected families.

```xml <problem> Maternal Autoantibody Related Autism (MARA) often goes undetected until clinical symptoms appear in children, delaying the implementation of tailored interventions that could improve outcomes. Early detection is hindered by the lack of accessible and accurate diagnostic tools available before or shortly after birth. </problem> <solution> MARAbio offers a maternal blood test designed to detect specific autoantibodies associated with MARA, providing a predictive assessment of a child's likelihood of developing severe autism. The test can be administered before pregnancy or as early as birth, enabling healthcare providers to identify potential cases of MARA before clinical symptoms manifest. By identifying these cases early, clinicians can initiate timely and tailored interventions, potentially mitigating the most severe effects of autism and improving outcomes for affected families. The company's technology provides an early assessment with a high degree of predictive accuracy. </solution> <features> - Maternal blood test to identify specific autoantibodies linked to MARA. - Predictive assessment of a child's likelihood of developing severe autism. - Testing available before pregnancy or as early as birth. - High predictive accuracy (over 90%) for severe autism in children with a positive MARA test in the mother. </features> <target_audience> The primary target audience includes healthcare providers, expecting mothers, and women planning to become pregnant who want to assess the risk of Maternal Autoantibody Related Autism (MARA) in their children. </target_audience> ```

What does MARAbio do?

Where is MARAbio located?

MARAbio is based in Mascoutah, United States.

When was MARAbio founded?

MARAbio was founded in 2016.

How much funding has MARAbio raised?

MARAbio has raised 25060000.

Location

Mascoutah, United States

Founded

2016

Funding

25060000

Employees

14 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

MARAbio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

marabio.com 300+

Founded 2016 – Mascoutah, United States

Funding

Estimated Funding

$20M+

Team (10+)

No team information available.

Company Description

Problem

Maternal Autoantibody Related Autism (MARA) often goes undetected until clinical symptoms appear in children, delaying the implementation of tailored interventions that could improve outcomes. Early detection is hindered by the lack of accessible and accurate diagnostic tools available before or shortly after birth.

Solution

MARAbio offers a maternal blood test designed to detect specific autoantibodies associated with MARA, providing a predictive assessment of a child's likelihood of developing severe autism. The test can be administered before pregnancy or as early as birth, enabling healthcare providers to identify potential cases of MARA before clinical symptoms manifest. By identifying these cases early, clinicians can initiate timely and tailored interventions, potentially mitigating the most severe effects of autism and improving outcomes for affected families. The company's technology provides an early assessment with a high degree of predictive accuracy.

Features

Maternal blood test to identify specific autoantibodies linked to MARA.

Predictive assessment of a child's likelihood of developing severe autism.

Testing available before pregnancy or as early as birth.

High predictive accuracy (over 90%) for severe autism in children with a positive MARA test in the mother.

Target Audience

The primary target audience includes healthcare providers, expecting mothers, and women planning to become pregnant who want to assess the risk of Maternal Autoantibody Related Autism (MARA) in their children.